Vitrafy enters U.S. Cell & Gene Therapy Market

Key points

• Vitrafy to install its cryopreservation ecosystem at Charter Medical's Innovation Hub
• Agreement marks Vitrafy's first entry into the U.S. cell and gene therapy market
• No revenue expected in initial 6-month term

Full summary

Vitrafy Life Sciences Ltd announced an agreement with Charter Medical to deploy its cryopreservation ecosystem at Charter Medical's Innovation Hub in North Carolina. This marks Vitrafy's first entry into the U.S. cell and gene therapy market, aiming to support cryopreservation and freeze curve optimization for Charter Medical's customers. The agreement will span an initial 6-month term with no revenue expected during this period. This deployment could open pathways for further commercial relationships in the U.S. CGT market.

Guidance

No revenue expected in initial 6-month term

Outlook

This agreement is a significant milestone for Vitrafy, providing an opportunity to demonstrate the capabilities of its cryopreservation ecosystem in a critical area of cell and gene therapy manufacturing.